Mary Caffrey

Mezigdomide, a powerful CELMoD, doubles PFS in relapsed or refractory multiple myeloma, offering hope when IMiDs stop working.

ASCO 2026 spotlights practice-changing cancer data: PROTEUS in prostate cancer, RAS(ON) inhibitor daraxonrasib, new bispecifics, and GLP-1 signals.

An Institute for Value-Based Medicine® event in Princeton highlights how the state's leading cancer care providers meet the needs of a diverse population.

ASCO highlights MorningSun results: subcutaneous mosunetuzumab offers a chemotherapy-free option for elderly patients with DLBCL, improving quality of life beyond R-CHOP.

Analyses to be presented at ASCO show zanubrutinib offers improved survival benefits and longer time to the next treatment over another BTK inhibitor in 2 common indications.

Johnetta Blakely, MD, MS, MMHC, discusses her new role as chief medical officer of the Community Oncology Alliance during an interview that will appear in the June issue of Evidence-Based Oncology.

Ontada research presented at ISPOR 2026 shows the NCCN Distress Thermometer can predict overall survival in metastatic cancers, but the relationship varies by cancer type.

Ontada finds that EHR-based education boosts NCCN guideline-concordant care for patients with HER2-low metastatic cancer, raising targeted treatment use among providers who took part in the education activities.

A CLL caregiver shares the reality of CAR T-cell therapy and why support for those who play this critical role will be essential to ensure access to these therapies.

US News & World Report reveals caregivers—often sandwich generation—face full-time hours, rising costs, burnout; CareYaya weighs in on demographics.

The next-generation BCL2 inhibitor is approved for adults with relapsed or refractory MCL who have received at least 2 lines of systemic treatment

The complexity of MCL calls for personalized therapeutic strategies, but prior authorization protocols may not recognize distinct patient needs.

Epcoritamab added to R2 sharply boosts follicular lymphoma responses, but infection risks and real-world feasibility raise tough treatment decisions.

Real-world data show zanubrutinib cuts atrial fibrillation, major bleeding, and mortality versus ibrutinib in B‑cell cancers—guiding safer BTK inhibitor choices.

COA's Patient Advocacy Network, or CPAN, was featured in the "From Our Partners" section of the May issue of Evidence-Based Oncology.

AI drives community oncology transformation as practice leaders offer examples of what is working in community oncology to streamline calls, triage, and documentation.

As CAR T-cell therapy reaches community oncology, practice leaders discuss the challenges of payer hurdles, single case agreements, apheresis costs and whether to pursue accreditation.

Policy experts discuss how PBM reforms came together, what changes are on the horizon, and what threats are looming for community oncology.

Bringing these curative treatments to more patients means making them available at the community practice level. But that's a big lift, according to experts who spoke at a COA session.

Results of a study using Flatiron Health and SEER data show that community oncology patients with metastatic breast cancer and metastatic NSCLC live longer, highlighting advantages of COA-backed local care.

COA's annual conference hits Orlando April 28, focusing on AI, targeted therapy innovation, and state-level oncology advocacy, explains cochair Johnetta Blakely, MD, MS, MMHC.

The COA Community Oncology Conference will tackle AI, the rollout of bispecifics and CAR T in the community setting, plus reimbursement, radiation oncology, and patient access strategies.

Mosunetuzumab, a bispecific, plus polatuzumab vedotin, an antibody-drug conjugate, deliver high response rates in relapsed MCL, potentially enabling outpatient community oncology treatment and wider patient access.

Off-the-shelf cema-cel clears MRD at more than triple the rate of observation alone—and may propel a shift to frontline use of CAR T-cell therapy when relapse is hard to detect.

Todd Doyle, MD, of OneOncology, warns that commercial payers lag on updating bundled codes, which has slashed radiation oncology revenue and risks community cancer access in 2026.

KFF Health Tracking Poll finds prior authorization tops patient hassles; Drew Altman, PhD, warns complexity delays care, hitting chronic patients hardest.

Lalan Wilfong, MD, a medical oncologist well known for his work in practice transformation, said he looks forward to creating "something more or less from scratch."

Nancy L. Lewis, MD, MBS, FACP, discusses her path from the clinic to biopharma and her goals as NCCN's new CSO, including health equity and faster drug development.

A phase 1 clinical trial specialist, Nancy L. Lewis, MD, MBS, FACP, most recently spent more than a decade at Novartis and was previously a faculty member at Fox Chase Cancer Center and Thomas Jefferson University Hospital.